[
  {
    "ts": null,
    "headline": "Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says",
    "summary": "Biogen (BIIB) demonstrated solid commercial execution across its core franchises, supporting a clear",
    "url": "https://finnhub.io/api/news?id=5fbb8e01a6b596686472cc51b4500c803817ddd6a269265a33b38844482980ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770655256,
      "headline": "Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says",
      "id": 138613442,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (BIIB) demonstrated solid commercial execution across its core franchises, supporting a clear",
      "url": "https://finnhub.io/api/news?id=5fbb8e01a6b596686472cc51b4500c803817ddd6a269265a33b38844482980ca"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?",
    "summary": "Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=41405dd86b09ed0279733ecbeca2fcb29dcd59a3254409eb2027a4744c51d62a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770655080,
      "headline": "Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?",
      "id": 138693763,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=41405dd86b09ed0279733ecbeca2fcb29dcd59a3254409eb2027a4744c51d62a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=29be500a4dbe071111b2482c401ab5720285c62b5f285b462fd44969faa71f9a",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770629113,
      "headline": "Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday",
      "id": 138413730,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/09/Los-Angeles--California---July-7-2025-El.jpeg?width=2048&height=1536",
      "related": "BIIB",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=29be500a4dbe071111b2482c401ab5720285c62b5f285b462fd44969faa71f9a"
    }
  },
  {
    "ts": null,
    "headline": "Biogen FY25 Earnings: Stable EPS, Amid Pressure From The Multiple Sclerosis Franchise",
    "summary": "Biogen (BIIB) outlook: rare disease & Alzheimerâs pivot, 2025 growth products hit $3.3B, EPS beats.",
    "url": "https://finnhub.io/api/news?id=d1d3b7a53d41c1eae442e80e4eb2ae0aade109fc634617de25656602dcb65572",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770619780,
      "headline": "Biogen FY25 Earnings: Stable EPS, Amid Pressure From The Multiple Sclerosis Franchise",
      "id": 138401194,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217256698/image_2217256698.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Biogen (BIIB) outlook: rare disease & Alzheimerâs pivot, 2025 growth products hit $3.3B, EPS beats.",
      "url": "https://finnhub.io/api/news?id=d1d3b7a53d41c1eae442e80e4eb2ae0aade109fc634617de25656602dcb65572"
    }
  },
  {
    "ts": null,
    "headline": "Reported Sunday, Eisai And Biogen Announce Priority Review Designation In China For Subcutaneous Autoinjector Formulation Of LEQEMBI Lecanemab For Treatment Of Early Alzheimer's Disease",
    "summary": "Reported Sunday, Eisai And Biogen Announce Priority Review Designation In China For Subcutaneous Autoinjector Formulation Of LEQEMBI Lecanemab For Treatment Of Early Alzheimer's Disease",
    "url": "https://finnhub.io/api/news?id=803b7809b98cfdc63008c2fdbb312112a82ce0326d9ffc1b39b5b985371c8c06",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770608446,
      "headline": "Reported Sunday, Eisai And Biogen Announce Priority Review Designation In China For Subcutaneous Autoinjector Formulation Of LEQEMBI Lecanemab For Treatment Of Early Alzheimer's Disease",
      "id": 138605992,
      "image": "",
      "related": "BIIB",
      "source": "Benzinga",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=803b7809b98cfdc63008c2fdbb312112a82ce0326d9ffc1b39b5b985371c8c06"
    }
  },
  {
    "ts": null,
    "headline": "Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China",
    "summary": "TOKYO and CAMBRIDGE, Mass., Feb. 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, whi",
    "url": "https://finnhub.io/api/news?id=93f795452350700602776ca2aedd9d990382c7bfda06ab6d2ddd4d965073763a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770602400,
      "headline": "Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China",
      "id": 138398348,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "TOKYO and CAMBRIDGE, Mass., Feb. 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, whi",
      "url": "https://finnhub.io/api/news?id=93f795452350700602776ca2aedd9d990382c7bfda06ab6d2ddd4d965073763a"
    }
  }
]